Tigecycline, Tygacil (tigecycline) is a small molecule pharmaceutical. Tigecycline was first approved as Tigecycline on 2005-06-15. It is used to treat bacteremia, bacterial infections, bacterial pneumonia, bacterial skin diseases, and bacteroides infections amongst others in the USA. It has been approved in Europe to treat bacterial infections, bacterial skin diseases, infectious skin diseases, intraabdominal infections, and soft tissue infections. Tygacil's patents are valid until 2033-04-07 (FDA).
|Indication||bacteremia, bacterial infections, bacterial pneumonia, bacterial skin diseases, bacteroides infections, clostridium infections, escherichia coli infections, haemophilus infections, infectious skin diseases, intraabdominal infections, klebsiella infections, legionellosis, soft tissue infections, staphylococcal infections, streptococcal infections|
|Drug Class||Antibiotics (tetracycline derivatives)|